About this trial
Clinical Trial
The goal of this clinical trial is to evaluate the effectiveness of two types of Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses in slowing myopia progression in children. It will also assess the safety of these lenses. The main questions it aims to answer are:
Do D.S.D.O. lenses reduce the progression of myopia as measured by changes in cycloplegic refraction and axial length? What adverse events do participants experience when wearing D.S.D.O. lenses? Researchers will compare two optical designs of D.S.D.O. lenses (Intervention Group1: Design 1; Intervention Group2: Design 2) to determine their relative efficacy in controlling myopia progression.
Participants will:
Wear assigned D.S.D.O. lenses daily for 12 months (except during sleep or unavoidable situations).
Attend clinic visits at baseline, 3, 6, 9, and 12 months for comprehensive eye examinations.
Maintain a diary recording daily wear time, visual symptoms, and any adverse events.
Eligibility criteria
Qualifiers
Age 6-14 years
Myopic spherical equivalent refraction between -0.75D and -4.00D (inclusive of -0.75D and -4.00D, based on cycloplegic refraction)
Astigmatism ≤1.50D
Anisometropia ≤1.50D
Disqualifiers
History of ocular trauma or surgery
Systemic diseases affecting visual function
Inability to cooperate with examinations
Poor compliance
Trial design
Treatments tested in this trial
- Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses